Jonathan Garnier1, Eddy Traversari2, Jacques Ewald2, Ugo Marchese2, Jean-Robert Delpero2, Olivier Turrini3. 1. Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. jonathan-garnier@hotmail.fr. 2. Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. 3. Department of Surgical Oncology, CRCM, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
Abstract
BACKGROUND: Although primary end-to-end anastomosis is preferred for portal vein-superior mesenteric vein (PV-SMV) reconstruction, interposition graft use may be required in some situations. We investigated the efficacy of polytetrafluoroethylene (PTFE) grafts when used during pancreatectomy in this context. METHODS: From 2014 to 2019, 19 patients who underwent pancreatectomy requiring PV-SMV reconstruction using ringed PTFE grafts were entered prospectively into a clinical database (NCT02871336, CNIL No. Sy50955016U). Unfractionated heparin was used during the first 24 h postoperatively. The administration of low-molecular-weight heparin was initiated twice a day (two injections of 1 mg/kg enoxaparin) on postoperative day 2 and was continued until the first clinical follow-up. Patency was assessed by CT scan before home discharge. Patients were switched to antiplatelet therapy (75 mg of aspirin-based drug Kardegic®) without a deadline. RESULTS: Pancreatoduodenectomy was the most commonly performed procedure (15 patients, 79%), and pancreatic duct adenocarcinoma was the predominant etiology (17 patients, 89%). The median PTFE graft diameter and length were 10 mm and 8 cm, respectively. The median clamping time was 25 min. The overall severe morbidity and 90-day mortality values were 21% and 10%, respectively. None of the patients experienced anticoagulation-related morbidity or PTFE graft-related infection. The 6-month PTFE graft patency rate was 68%. Patients who underwent distal pancreatectomy showed a higher late thrombosis rate than those who underwent a pancreaticoduodenectomy (50% vs. 8%, p = 0.049). The median long-term PTFE graft patency duration was 37 months. CONCLUSIONS: PTFE reconstruction can be safely performed with simple perioperative management in cases requiring interposition graft use.
BACKGROUND: Although primary end-to-end anastomosis is preferred for portal vein-superior mesenteric vein (PV-SMV) reconstruction, interposition graft use may be required in some situations. We investigated the efficacy of polytetrafluoroethylene (PTFE) grafts when used during pancreatectomy in this context. METHODS: From 2014 to 2019, 19 patients who underwent pancreatectomy requiring PV-SMV reconstruction using ringed PTFE grafts were entered prospectively into a clinical database (NCT02871336, CNIL No. Sy50955016U). Unfractionated heparin was used during the first 24 h postoperatively. The administration of low-molecular-weight heparin was initiated twice a day (two injections of 1 mg/kg enoxaparin) on postoperative day 2 and was continued until the first clinical follow-up. Patency was assessed by CT scan before home discharge. Patients were switched to antiplatelet therapy (75 mg of aspirin-based drug Kardegic®) without a deadline. RESULTS: Pancreatoduodenectomy was the most commonly performed procedure (15 patients, 79%), and pancreatic duct adenocarcinoma was the predominant etiology (17 patients, 89%). The median PTFE graft diameter and length were 10 mm and 8 cm, respectively. The median clamping time was 25 min. The overall severe morbidity and 90-day mortality values were 21% and 10%, respectively. None of the patients experienced anticoagulation-related morbidity or PTFE graft-related infection. The 6-month PTFE graft patency rate was 68%. Patients who underwent distal pancreatectomy showed a higher late thrombosis rate than those who underwent a pancreaticoduodenectomy (50% vs. 8%, p = 0.049). The median long-term PTFE graft patency duration was 37 months. CONCLUSIONS:PTFE reconstruction can be safely performed with simple perioperative management in cases requiring interposition graft use.
Authors: Monica M Dua; Thuy B Tran; Jill Klausner; Kim J Hwa; George A Poultsides; Jeffrey A Norton; Brendan C Visser Journal: HPB (Oxford) Date: 2015-07-30 Impact factor: 3.647
Authors: Iman Khaoudy; Olivier Farges; Emmanuel Boleslawski; Eric Vibert; Olivier Soubrane; Mustapha Adham; Jean Yves Mabrut; Laurent Christophe; Philippe Bachellier; Olivier Scatton; Yves-Patrice Le Treut; Jean Marc Regimbeau Journal: Ann Surg Date: 2018-11 Impact factor: 12.969
Authors: Maximilian Bockhorn; Faik G Uzunoglu; Mustapha Adham; Clem Imrie; Miroslav Milicevic; Aken A Sandberg; Horacio J Asbun; Claudio Bassi; Markus Büchler; Richard M Charnley; Kevin Conlon; Laureano Fernandez Cruz; Christos Dervenis; Abe Fingerhutt; Helmut Friess; Dirk J Gouma; Werner Hartwig; Keith D Lillemoe; Marco Montorsi; John P Neoptolemos; Shailesh V Shrikhande; Kyoichi Takaori; William Traverso; Yogesh K Vashist; Charles Vollmer; Charles J Yeo; Jakob R Izbicki Journal: Surgery Date: 2014-02-07 Impact factor: 3.982
Authors: Sjors Klompmaker; Jony van Hilst; Sarah L Gerritsen; Mustapha Adham; M Teresa Albiol Quer; Claudio Bassi; Frederik Berrevoet; Ugo Boggi; Olivier R Busch; Manuela Cesaretti; Raffaele Dalla Valle; Benjamin Darnis; Matteo De Pastena; Marco Del Chiaro; Robert Grützmann; Markus K Diener; Traian Dumitrascu; Helmut Friess; Arpad Ivanecz; Anastasios Karayiannakis; Giuseppe K Fusai; Knut J Labori; Carlo Lombardo; Santiago López-Ben; Jean-Yves Mabrut; Willem Niesen; Fernando Pardo; Julie Perinel; Irinel Popescu; Geert Roeyen; Alain Sauvanet; Raj Prasad; Christian Sturesson; Mickael Lesurtel; Jorg Kleeff; Roberto Salvia; Marc G Besselink Journal: Ann Surg Oncol Date: 2018-03-12 Impact factor: 5.344